Thus, they are not only selective for superoxide removal but also react with the product of the dismutation, hydrogen peroxide, and the secondary oxidant, peroxynitrite. This may or may not be clinically useful or relevant, but mechanism is something that must be noted when discussing pharmacology of a pharmaceutical agent. Furthermore, it is irritating that the authors attempt to discount other compounds that are currently in human clinical trials [e.g., Mn(II)pentaazamacrocyclic ligand complexes] by claiming that they are acid unstable. This is misleading given that some of the authors of this letter have reported previously on the high kinetic and thermodynamic stability of members of this class of compounds (e.g., M40403). In fact, compounds of this class, including GC4419, are largely unmetabolized (>90% unchanged) and excreted almost entirely intact. In summary, given the focus of our review on the advanced clinical stage of antioxidant drugs, we consider it free of obvious bias, including conflict of interest. By comparison, it would have been appropriate for the authors of the letter, in the version provided to us, to state any potential conflict of interest that may have contributed to their choice of compound(s).
